Incylix Bio

Incyclix Bio is a biopharmaceutical company developing precision cancer treatments that target cyclin-dependent kinases (CDKs) to address aberrant cell proliferation in tumors such as ovarian, breast, and lung cancers. The company's lead candidate, INX-315, is a selective CDK2 inhibitor currently in clinical development.